Potential role for a panel of immunohistochemical markers in the management of endometrial carcinoma

16Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Background: In order to improve the efficacy of endometrial carcinoma (EC) treatment, identifying prognostic factors for high risk patients is a high research priority. This study aimed to assess the relationships among the expression of estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and the different histopathological prognostic parameters in EC and to assess the value of these in the management of EC. Methods: We examined 109 cases of EC. Immunohistochemistry for ER, PR, HER2, and Ki-67 were evaluated in relation to age, tumor size, International Federation of Gynecology and Obstetrics (FIGO) stage and grade, depth of infiltration, cervical and ovarian involvement, lymphovascular space invasion (LVSI), and lymph node (LN) metastasis. Results: The mean age of patients in this study was 59.8 ± 8.2 years. Low ER and PR expression scores and high Ki-67 expression showed highly significant associations with non-endometrioid histology (p = .007, p < .001, and p < .001, respectively) and poor differentiation (p = .007, p < .001, and p

Cite

CITATION STYLE

APA

Salama, A., Arafa, M., ElZahaf, E., Shebl, A. M., Awad, A. A. E. H., Ashamallah, S. A., … Abdel-Hady, E. S. M. (2019). Potential role for a panel of immunohistochemical markers in the management of endometrial carcinoma. Journal of Pathology and Translational Medicine, 53(3), 164–172. https://doi.org/10.4132/jptm.2019.02.12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free